德谷胰岛素联合西格列汀二甲双胍治疗难治性2型糖尿病的临床研究  

Clinical Study on Degu Insulin Combined with Sitagliptin Phosphate/Metformin Hy drochloride in the Treatment of Refrac-tory Type 2 Diabetes Mellitus

作　　者：万晓娟[1] 杜静[1] WAN Xiaojuan;DU Jing(Department of Endocrinology and Nephrology,Yellow River Center Hospital of Yellow River Conservancy Commission,Zhengzhou 450003,China)

机构地区：[1]黄河水利委员会黄河中心医院内分泌肾内科,河南郑州450003

出　　处：《临床医学工程》2024年第7期799-800,共2页Clinical Medicine & Engineering

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20210568)。

摘　　要：目的探讨德谷胰岛素联合西格列汀二甲双胍治疗难治性2型糖尿病患者的临床效果。方法选取2021年5月至2023年3月我院收治的84例难治性2型糖尿病住院患者,随机分为试验组(42例)和参照组(42例)。参照组采用西格列汀二甲双胍治疗,试验组采用德谷胰岛素联合西格列汀二甲双胍治疗。比较两组的血糖水平、低血糖发生情况。结果治疗12周后,两组空腹血糖(FPG)、餐后2h血糖(2hPBG)和糖化血红蛋白(HbA1c)水平降低,且试验组FPG、2hPBG、HbA1c水平低于参照组(P<0.05)。试验组治疗期间低血糖发生率为11.90%,与参照组的9.52%无统计学差异(P>0.05)。结论德谷胰岛素联合西格列汀二甲双胍治疗难治性2型糖尿病患者的控糖效果更佳,且未明显增加低血糖发生风险,安全性较高,值得临床推广。Objective To explore the clinical effect of Degu insulin combined with sitagliptin phosphate/metformin hydrochloride in the treatment of patients with refractory type 2 diabetes mellitus.Methods 84 patients with refractory type 2 diabetes mellitus admitted to our hospital from May 2021 to March 2023 were selected and randomly divided into experimental group(42 cases)and reference group(42 cases).The reference group was treated with sitagliptin phosphate/metformin hydrochloride,and the experimental group was treated with Degu insulin combined with sitagliptin phosphate/metformin hydrochloride.The blood glucose levels and hypoglycemia were compared between the two groups.Results After 12 weeks of treatment,the fasting blood glucose(FPG),2-hour postprandial blood glucose(2hPBG),and hemoglobin(HbA1c)levels of the two groups decreased,and the FPG,2hPBG,and HbAlc levels of the experimental group were lower than those of the reference group(P<0.05).During the treatment,no statistical difference was found in the incidence of hypoglycemia(11.90%vs.9.52%)between the two groups(P>0.05).Conclusions Degu insulin combined with sitagliptin phosphate/metformin hydrochloride has better glycemic control effect in the treatment of patients with refractory type 2 diabetes mellitus,and does not significantly increase the risk of hypoglycemia in patients with higher safety,which is worthy of clinical promotion.

关 键 词：难治性2型糖尿病 西格列汀二甲双胍 德谷胰岛素 治疗效果 

分 类 号：R587.1[医药卫生—内分泌]